Clinical trials: Intrahepatic Cholangiocarcinoma
Biliary Tract Neoplasms, Advanced Cancer
A Phase IIb Randomized Clinical Trial of Immune Checkpoint Inhibitor-based Maintenance Therapy in Patients With Advanced Biliary Tract Cancer
"Biliary tract cancer (BTC) is a rare malignancy with a poor prognosis. Most patients present with unresectable disease, and even after curative-intent resection, recurrence is common.
- Conditions
- Biliary Tract Neoplasms, Advanced Cancer, Immunotherapy
- Trial name
- NCT07269158
- Testing
- Durvalumab or Pembrolizumab, Durvalumab or Pembrolizumab + Levnatinib, Durvalumab or Pembrolizumab + Venadaparib
- Where
- South Korea
- Volunteers
- 160 people
- Sponsor
- Yonsei University
Perihilar Cholangiocarcinoma
Extent of Intrahepatic Infiltration of Perihilar Cholangiocarcinoma
The extent of intrahepatic infiltration of perihilar cholangiocarcinoma (PHCC) remains unclear. This research aimed to explore the pattern and extent of intrahepatic infiltration of PHCC to guide surgical treatment and…
- Trial name
- NCT06357117
- Where
- China
- Volunteers
- 62 people
- Sponsor
- Beijing Tsinghua Chang Gung Hospital
Intrahepatic Cholangiocarcinoma
Gemcitabine and Oxaliplatin Chemotherapy With or Without a Floxuridine and Dexamethasone Pump in People With Cholangiocarcinoma That Cannot Be Removed With Surgery
This study will compare the safety and effects of HAI floxuridine and dexamethasone combined with the standard chemotherapy drugs gemcitabine and oxaliplatin (GemOx) with those of GemOx alone in people with untreated…
- Trial name
- NCT04891289
- Testing
- Gemcitabine, Oxaliplatin, Dexamethasone
- Where
- 11 sites in United States, Netherlands
- Volunteers
- 164 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Intrahepatic Cholangiocarcinoma (Icc)
PErioperative CISGEM + Rilvegostomig in High-Risk Resectable Intra Hepatic CholangioCarcinoma
The goal of this trial is to determine whether the combination of CISGEM and Rilvegostomig during the perioperative period works to improve outcomes of patient undergoing surgery of high-risk of intrahepatic cholangiocarcinoma
- Trial name
- PEHRICCA (NCT07128290)
- Testing
- CISGEM + Rilvegostomig
- Where
- 9 sites in France
- Volunteers
- 49 people
- Sponsor
- Federation Francophone de Cancerologie Digestive
FGFR2 Amplification, FGFR2 Gene Mutation
REFOCUS: A First-in-Human Study of Highly Selective FGFR2 Inhibitor, RLY-4008, in Patients With ICC and Other Advanced Solid Tumors
This is a Phase 1/2, open-label, FIH study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PDy), and antineoplastic activity of RLY-4008, a potent and highly selective FGFR2 inhibitor, in…
- Conditions
- FGFR2 Amplification, FGFR2 Gene Mutation, FGFR2 Gene Fusion/Rearrangement, FGFR2 Gene Translocation
- Trial name
- NCT04526106
- Testing
- RLY-4008
- Where
- 48 sites in United States, Australia and 11 more
- Volunteers
- 490 people
- Sponsor
- Elevar Therapeutics
Intrahepatic Cholangiocarcinoma
Neoantigen Vaccine Plus Capecitabine as Adjuvant Therapy for Intrahepatic Cholangiocarcinoma After Radical Resection
This study is a single-arm, open-label, exploratory clinical trial, with the primary objective to evaluate the efficacy and safety of the Neoantigen Vaccine plus capecitabine for the treatment of high-intermediate risk recurrent…
- Trial name
- NCT06406816
- Testing
- Neoantigen Vaccine plus Capecitabine
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Yongyi Zeng
Hepatocellular Carcinoma Stage IIIB, Cholangiocarcinoma, Intrahepatic
Evaluation the Palliative Effects of Colchicine on Primary Hepatic Malignant Tumors Unable to Receive Curative Treatment
This trial is to evaluate the palliative effects of colchicine on primary hepatic malignancy using the Department of Health R.O.C. approved doses and methods of administration.
- Conditions
- Hepatocellular Carcinoma Stage IIIB, Cholangiocarcinoma, Intrahepatic, Cholangiocarcinoma; With Hepatocellular Carcinoma, Hepatocellular Carcinoma Stage IV
- Trial name
- NCT04264260
- Testing
- Colchicine Tablets
- Where
- Taiwan
- Volunteers
- 42 people
- Sponsor
- Kaohsiung Medical University Chung-Ho Memorial Hospital
Biliary Tract Cancer (BTC)
Study on Sequential Cryoablation, Relaforp Alpha, and Chemotherapy for Bile Duct Tumors
This study is a prospective, multicenter, single-arm, open-label Phase II clinical trial, planned to enroll 30 patients with unresectable locally advanced or metastatic iCCA/GBC.
- Trial name
- NCT07726446
- Testing
- PD-1 and chemotherapy, cryoablation
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Intrahepatic Cholangiocarcinoma
Lenvatinib Plus Sintilimab in Patients With Immune Checkpoint Inhibitor Previously Treated Advanced Liver Cancer
The objective of this study is to evaluate the efficacy and safety of Lenvatinib plus Sintilimab in patients with advanced liver cancer progressed after treatment with immune checkpoint inhibitors.
- Trial name
- NCT05010681
- Testing
- Sintilimab, Lenvatinib
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Fudan University
Cholangiocarcinoma
Durvalumab and Tremelimumab With Platinum-based Chemotherapy in Intrahepatic Cholangiocarcinoma (ICC)
This pilot trial will be used to assess the activity, safety and feasibility of doublet immunotherapy and platinum-based chemotherapy in resectable intrahepatic cholangiocarcinoma with high risk features.
- Trial name
- ICC (NCT04989218)
- Testing
- Novel combination of chemotherapy and immunotherapy
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- University of Alabama at Birmingham
Gallbladder Carcinoma, Metastatic Cholangiocarcinoma
Atezolizumab With or Without Cobimetinib in Treating Patients With Metastatic Bile Duct Cancer That Cannot Be Removed by Surgery or Gallbladder Cancer
This randomized phase II trial studies how well atezolizumab with or without cobimetinib works in treating patients with bile duct cancer that has spread to other places in the body (metastatic) and cannot be removed by surgery…
- Conditions
- Gallbladder Carcinoma, Metastatic Cholangiocarcinoma, Stage III Intrahepatic Cholangiocarcinoma AJCC v8, Stage IV Intrahepatic Cholangiocarcinoma AJCC v8
- Trial name
- NCT03201458
- Testing
- Atezolizumab, Biopsy, Biospecimen Collection
- Where
- 41 sites in United States
- Volunteers
- 86 people
- Sponsor
- National Cancer Institute (NCI)
Cholangiocarcinoma, Cholangiocarcinoma, Intrahepatic
Detecting Lymph Node Metastasis in Intrahepatic Cholangiocarcinoma (LyMIC)
Lymph node metastasis (LNM) is a major prognostic factor in intrahepatic cholangiocarcinoma (ICC), and accurate preoperative prediction of the presence or absence of LNM has significant clinical implications in determining…
- Conditions
- Cholangiocarcinoma, Cholangiocarcinoma, Intrahepatic, Cholangiocarcinoma Resectable, Cholangiocarcinoma; Liver
- Trial name
- LyMIC (NCT06381648)
- Testing
- LyMIC (Lymph Node Metastasis in Intrahepatic Cholangiocarcinoma)
- Where
- 4 sites in United States, Japan
- Volunteers
- 230 people
- Sponsor
- City of Hope Medical Center
Liver and Intrahepatic Bile Duct Carcinoma, Stage III Intrahepatic Cholangiocarcinoma AJCC v8
mFOLFIRINOX Followed by Hepatic Arterial Infusion of Floxuridine and Dexamethasone With Systemic mFOLFIRI for Unresectable Liver-dominant Intrahepatic Cholangiocarcinoma
This phase II trial studies the efficacy and safety of systemic induction of mFOLFIRINOX, followed by hepatic arterial infusion (HAI) floxuridine-dexamethasone administered concurrently with systemic mFOLFIRI in treating patients…
- Conditions
- Liver and Intrahepatic Bile Duct Carcinoma, Stage III Intrahepatic Cholangiocarcinoma AJCC v8, Stage IIIA Intrahepatic Cholangiocarcinoma AJCC v8, Stage IIIB Intrahepatic Cholangiocarcinoma AJCC v8
- Trial name
- NCT04251715
- Testing
- Dexamethasone, Floxuridine, Implanted Medical Device
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- OHSU Knight Cancer Institute
Biliary Tract (Intrahepatic, Extrahepatic Cholangiocarcinoma, Gall Bladder) Cancer
Study of GEMOX(Gemcitabine/Oxaliplatin) Versus XELOX(Xeloda/Oxaliplatin) in Advanced Biliary Tract Carcinoma
The objective of the trial is to compare Progression free survival between GEMOX (gemcitabine/oxaliplatin)vs XELOX(capecitabine/oxaliplatin)in metastatic or unresectable Biliary tract carcinoma patients.
- Trial name
- NCT01470443
- Testing
- Oxaliplatin
- Where
- South Korea
- Volunteers
- 240 people
- Sponsor
- Samsung Medical Center
Intrahepatic Cholangiocarcinoma
The Purpose of This Research Study is to See if Combining Gemcitabine, Cisplatin and Durvalumab Chemotherapy Treatments With a Direct Tumor Therapy Yittrium-90 (Y-90) Will Work Better Together to Shrink Tumors and Control Cancer
The purpose of this research is to see if combining gemcitabine, cisplatin and Durvalumab chemotherapy treatments with a direct tumor therapy called Yittrium-90, will work better together to shrink the tumor and control cancer.
- Trial name
- NCT05422690
- Testing
- Induction Chemotherapy Triplet Therapy, Concurrent Y-90 treatment, Consolidation Doublet Therapy:
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Inova Health Care Services
Hepatocellular Carcinoma (HCC), Intrahepatic Cholangiocarcinoma (Icc)
Study Assessing PET Imaging With Zirconium-labelled Girentuximab in Patients With HCC, BTC or NEN
Precision medicine represents a major goal in oncology. It has its underpinning in the identification of biomarkers with diagnostic, prognostic, or predictive values.
- Conditions
- Hepatocellular Carcinoma (HCC), Intrahepatic Cholangiocarcinoma (Icc), Neuroendocrine Tumors
- Trial name
- ELEGANCE (NCT06735560)
- Testing
- 89Zr-TLX250 PET/CT
- Where
- 2 sites in France
- Volunteers
- 60 people
- Sponsor
- Nantes University Hospital
ICC
Treatment of Advanced Intrahepatic Cholangiocarcinoma
The purpose of this study is to evaluate the efficacy and safety of Levamisole Hcl in the treatment of patients with advanced intrahepatic cholangiocarcinoma.
- Trial name
- TAICC (NCT03940378)
- Testing
- Levamisole Hydrochloride, Anlotinib Hydrochloride Capsules
- Where
- China
- Volunteers
- 152 people
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
Intrahepatic Cholangiocarcinoma, Chemotherapy Effect
Low-dose Gemcitabine and Cisplatin and PD-1/PD-L1 Antibody Therapy in Intrahepatic Cholangiocarcinoma
In this phase 2 study, researchers aimed to evaluate the efficacy and safety of low-dose gemcitabine and cisplatin chemotherapy and the immune checkpoint inhibitor PD-1/PD-L1 antibody in patients with advanced and unresectable…
- Conditions
- Intrahepatic Cholangiocarcinoma, Chemotherapy Effect, Immunotherapy
- Trial name
- NCT06567600
- Testing
- Low-dose Gemcitabine and Cisplatin Chemotherapy plus PD-1/PD-L1Antibody
- Where
- China
- Volunteers
- 43 people
- Sponsor
- Third Affiliated Hospital, Sun Yat-Sen University
Stage III Intrahepatic Cholangiocarcinoma, Stage IVA Intrahepatic Cholangiocarcinoma
Radiation Therapy vs. Observation Following Gemcitabine and Cisplatin for Inoperable Localized Liver Cancer
This randomized phase III trial studies how well gemcitabine hydrochloride and cisplatin with or without radiation therapy work in treating patients with localized liver cancer that cannot be removed by surgery.
- Trial name
- NCT02200042
- Testing
- Image Guided Radiation Therapy
- Where
- 34 sites in United States, Canada
- Volunteers
- 1 people
- Sponsor
- NRG Oncology
Intrahepatic Cholangiocarcinoma, Cholangiocarcinoma, Intrahepatic
Liver Transplantation in Intrahepatic Cholangiocarcinoma
The aim of the current study is to determine the potential efficacy of liver transplantation in the form of patients' overall survival (OS) after neoadjuvant systemic therapy in patients with biologically responsive locally…
- Trial name
- NCT06140134
- Testing
- Liver Transplant
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- Rutgers, The State University of New Jersey